Silence Therapeutics plc
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
8. Benefit from R&D credit
An additional $0.8 million was recognized in respect of research and development tax credits in the three months ended June 30, 2026 (three months ended June 30, 2025: $2.4 million).
$1.5 million was recognized in respect of research and development tax credits in the six months ended June 30, 2026 (six months ended June 30, 2025: $5.1 million).
The current asset at June 30, 2026 was $9.3 million, comprised of $1.5 million in respect of research and development activities for the six months ended June 30, 2026 and $7.5 million in respect of the year ended December 31, 2025. In the six months ended June 30, 2026, the Group received $14.2 million related to the receipt of the 2024 claim for past research and development tax credits. The remaining change in the balance from December 31, 2025 is due to foreign currency exchange differences as the balance is denominated in GBP.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.